USPTO serial 79365404
DEVELOPICK
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 22, 2024
- Examiner
- BLAZICH, JOAN MICHELE
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with DEVELOPICK?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian P. Gregg
Brian P. Gregg McNees Wallace & Nurick100 Pine StreetHarrisburg, PA 17108UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 040 | Custom manufacture of polyclonal antibodies for pharmaceutical use; custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; processing of plant hormones being phytohormones; processing of medicinal materials; processing of pharmaceutical preparations; custom manufacture of pharmaceuticals; processing of pharmaceuticals; custom manufacture of pharmaceutical bispecific antibodies; processing of chemical reagents | ACTIVE | — |
| 042 | Advisory services relating to technological research in the field of pharmaceutical manufacturing processes; advisory services relating to scientific analysis in the field of nucleic acids; research relating to science, namely, scientific research; conducting of technical feasibility studies, namely, conducting of feasibility studies in the field of new technologies; multiple nucleic acid scientific analysis; multiple nucleic check, namely, materials testing; analysis of materials; materials testing and evaluation; chemical analysis services for use in the testing of material; molecular analysis, namely, scientific analysis in the field of molecular biology; advisory services relating to biotechnology; technical management advisory services relating to biotechnology, namely, scientific research consulting, biotechnology consultancy services; biochemical analysis; advisory services relating to biochemistry research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; design of new products for others; technical advice relating to safety, namely, consumer product safety testing consultation; pharmaceutical research and development; pharmaceutical products evaluation; clinical research in the field of medicines; services for assessing the efficiency of pharmaceuticals, namely, testing of pharmaceuticals; testing of raw materials; fusion protein analysis being testing of raw materials; computer programming services in the medical field; computer project management services relating to imaging medical data; medicine research being medical research; scientific analysis and quality evaluation of medical product development; pharmaceutical technology advisory service, namely, computer technology consultancy; pharmaceutical product evaluation; providing scientific and medical information on the testing, inspection and research of medical products; pharmaceutical product evaluation; scientific laboratory services relating to the production of bispecific antibody; bispecific antibody drug development; double antibody reagent scientific research and development; evaluating of clinical trial progress, namely, conducting clinical trials for others; clinical research, namely, conducting clinical trials for others; evaluation of product development being product quality evaluation; product safety testing; quality assurance consultancy in the field of pharmaceuticals; quality assessment being product testing; scientific research advisory services relating to chemical reagents; evaluation of chemical syntheses being product quality evaluation | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks owned by Samsung Biologics Co., Ltd.
- Other trademarks in Class 040
- Other trademarks in Class 042
- Similar marks named DEVELOPICK
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 12, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 25, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 25, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jan 22, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Oct 22, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 22, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Aug 31, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Aug 14, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 14, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Aug 6, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Aug 6, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 17, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 1, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 14, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 14, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 14, 2024 | ALIE | ASSIGNED TO LIE | — |
| May 14, 2024 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| May 14, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2024 | PETG | PETITION TO REVIVE-GRANTED | — |
| May 14, 2024 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| Nov 22, 2023 | RFNP | REFUSAL PROCESSED BY IB | — |
| Nov 2, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Nov 2, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 2, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 1, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 30, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 21, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 17, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 16, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |